Visualitza per autor "Bauer, Todd"
Ara mostrant els elements 1-7 d 7
-
A pragmatic guide for management of adverse events associated with lorlatinib
Liu, Geoffrey; Stratmann, Jan; Ou, Sai-Hong; Mok, Tony; MAZIERES, JULIEN; Bauer, Todd; FELIP, ENRIQUETA (Elsevier, 2024-03-14) -
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Shaw, Alice Tsang; Johnson, Melissa L.; Navarro Mendivil, Alejandro; Gainor, Justin F.; Thurm, Holger; Felip Font, Enriqueta; Bauer, Todd (Springer, 2020-02) -
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor
Harding, James J.; Tan, Daniel S. W.; Bedard, Philippe L.; Rodon Ahnert, Jordi; Doi, Toshihiko; Bauer, Todd (Springer, 2019-04-15) -
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
Schuler, Martin; Berardi, R.; Lim, Darren Wan-Teck; de Jonge, M.; Azaro Pedrazzoli, Analía Beatriz; Bauer, Todd (Elsevier, 2020-06) -
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer
Iadeluca, Laura; Shaw, Alice Tsang; de Marinis, Filippo; Felip Font, Enriqueta; Solomon, Benjamin; Bauer, Todd; Mazieres, Julien (Elsevier, 2022-12) -
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
Su, Wu-Chou; Schuler, Martin; Nam, Do-Hyun; Lim, Darren Wan-Teck; Azaro Pedrazzoli, Analía Beatriz; Bauer, Todd; Bang, Yung-Jue (Wiley, 2020-02) -
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer
Solomon, Benjamin; Bauer, Todd; Mok, Tony; MAZIERES, JULIEN; de Marinis, Filippo; FELIP, ENRIQUETA; Liu, Geoffrey (Future Medicine, 2023-05)